117 related articles for article (PubMed ID: 27418432)
1. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association.
Gruber S; Chakravarty A; Heckbert SR; Levenson M; Martin D; Nelson JC; Psaty BM; Pinheiro S; Reich CG; Toh S; Walker AM
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):973-81. PubMed ID: 27418432
[TBL] [Abstract][Full Text] [Related]
2. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.
Xu Y; Zhou X; Suehs BT; Hartzema AG; Kahn MG; Moride Y; Sauer BC; Liu Q; Moll K; Pasquale MK; Nair VP; Bate A
Drug Saf; 2015 Aug; 38(8):749-65. PubMed ID: 26055920
[TBL] [Abstract][Full Text] [Related]
3. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases.
Schuemie MJ; Gini R; Coloma PM; Straatman H; Herings RM; Pedersen L; Innocenti F; Mazzaglia G; Picelli G; van der Lei J; Sturkenboom MC
Drug Saf; 2013 Oct; 36 Suppl 1():S159-69. PubMed ID: 24166232
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China.
Yang Y; Zhou X; Gao S; Lin H; Xie Y; Feng Y; Huang K; Zhan S
Drug Saf; 2018 Jan; 41(1):125-137. PubMed ID: 28815480
[TBL] [Abstract][Full Text] [Related]
5. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
Int J Evid Based Healthc; 2005 Jul; 3(6):147-67. PubMed ID: 21631747
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.
Zhou X; Murugesan S; Bhullar H; Liu Q; Cai B; Wentworth C; Bate A
Drug Saf; 2013 Feb; 36(2):119-34. PubMed ID: 23329543
[TBL] [Abstract][Full Text] [Related]
7. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'.
Gagne JJ; Schneeweiss S
Stat Med; 2013 Mar; 32(6):1073-4. PubMed ID: 23413214
[No Abstract] [Full Text] [Related]
8. Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
[TBL] [Abstract][Full Text] [Related]
9. Effects of expanding the look-back period to all available data in the assessment of covariates.
Nakasian SS; Rassen JA; Franklin JM
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):890-899. PubMed ID: 28397352
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
11. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases.
Li X; Hui S; Ryan P; Rosenman M; Overhage M
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):503-9. PubMed ID: 23408560
[TBL] [Abstract][Full Text] [Related]
12. Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).
Hauben M; Aronson JK; Ferner RE
Drug Saf; 2016 May; 39(5):421-32. PubMed ID: 26879560
[TBL] [Abstract][Full Text] [Related]
13. Developing alerting thresholds for prospective drug safety monitoring.
Wangge G; Schneeweiss S; Glynn RJ; Gagne JJ
Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):755-62. PubMed ID: 26596260
[TBL] [Abstract][Full Text] [Related]
14. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
Ryan PB; Madigan D; Stang PE; Overhage JM; Racoosin JA; Hartzema AG
Stat Med; 2012 Dec; 31(30):4401-15. PubMed ID: 23015364
[TBL] [Abstract][Full Text] [Related]
15. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned.
Carnahan RM; Moores KG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():82-9. PubMed ID: 22262596
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of Mapping Austrian Health Claims Data to the OMOP Common Data Model.
Haberson A; Rinner C; Schöberl A; Gall W
J Med Syst; 2019 Sep; 43(10):314. PubMed ID: 31494719
[TBL] [Abstract][Full Text] [Related]
17. Design and analysis of drug safety studies, with special reference to sporadic drug use and acute adverse reactions.
Feldmann U
J Clin Epidemiol; 1993 Mar; 46(3):237-44. PubMed ID: 8455048
[TBL] [Abstract][Full Text] [Related]
18. Review of company postmarketing surveillance studies.
Waller PC; Wood SM; Langman MJ; Breckenridge AM; Rawlins MD
BMJ; 1992 Jun; 304(6840):1470-2. PubMed ID: 1611368
[TBL] [Abstract][Full Text] [Related]
19. Symmetry analysis for monitoring safety of newly marketed drugs.
Kubota K
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):349-51. PubMed ID: 26440748
[TBL] [Abstract][Full Text] [Related]
20. Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.
Zhou X; Bao W; Gaffney M; Shen R; Young S; Bate A
J Biopharm Stat; 2018; 28(4):668-681. PubMed ID: 29157113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
